Fig. 2From: Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysisPooled pCR outcome of TA-treated Asian breast cancer patients according to molecular subtypes. Forest plots describing the random effect ORs and 95% CIs from studies assessing the association of pCR outcome in NAC TA-treated breast cancer patients between (A) HER2E and luminal-like; (B) HER2E and luminal A; (C) HER2E and luminal B; (D) HER2E and luminal, combined; and (E) TNBC and luminal-like; (F) TNBC and luminal A; (G) TNBC and luminal B; and (H) TNBC and luminal, combined. I2 and p-value for X2 of heterogeneity are reported for each group analysisBack to article page